Back to News
Guidance Oxford AstraZeneca Vaccine for under 40s
Posted on 12 May 2021
The Joint Committee for Vaccinations & Immunisations has updated its guidance for the use of the Oxford AstraZeneca Covid-19 vaccine. It has recommended that people under 40 are offered an alternative vaccination where available and where this will not cause delays to people having the vaccine.
This follows ongoing reviews by the independent regulator, the MHRA, of a very small number of people in the UK who have developed a rare blood-clotting condition since having the Oxford AstraZeneca Covid-19 vaccine. Both the JCVI and MHRA have emphasised that the risk is extremely small – just over 10 people in every million have developed this condition - and that the benefits of the vaccine outweigh the risks for the vast majority of people.
However, given current vaccines supplies and that infection rates are increasingly coming under control in the UK, the JCVI has recommended taking this precautionary measure for younger people. This takes into account that this rare condition is seen more often in younger people and that the risks from COVID-19 decrease with age.
The latest guidance is as follows:
Everyone who has had the AstraZeneca vaccine should still have a second dose of the AstraZeneca vaccine, irrespective of age, unless they suffered any serious side effects after their first vaccination. Having the second dose is very important as it will give you higher and longer lasting protection.
Please see the updated leaflet below that has been produced by Public Health England and the NHS to answer any questions you may have
Leaflet on COVID-19 vaccination and blood clotting